Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Loving these bargains. They will not last, people will be panic chasing in $$$ land soon enough $BIXT
$BIXT had three golden crosses already. Nice peeerdy Money green curve back up late today and the gap up covered
**Huge update on $BIXT just out. Also the First Lady of the USA has Covid, announced late yesterday.** BIXT is in the buying zone, and not many cheap shares left before this makes a huge run IMO.
https://www.linkedin.com/pulse/small-pharma-poised-find-next-wonder-drug-after-big-pharmas-sheikh/
Are you offering to pay have off the convertible notes? And fund BIXT the right way?
I recall disgruntled investors that were unhappy with Moderna's lack of a product and revenue before Covid, threatening the CEO with suits over dilution and cash burn with no product or revenue, when Covid came out of left field saved Moderna's asses. No I am not going to dig up the proof. Lets move on...
About 6 months ago the entire US Banking system nearly failed... Months later US nearly defaulted on its debt..
3-4 months ago the money maggots all said "covid is over, no one cares".
The FED is trying to kill inflation and investing (which is and has been killing funding for biotechs), and the FED does not care about collateral damage.
I tried to tell them Covid ain't over. Did they listen? No. They are waking back up now. And fast..
a 20% increased Covid death rate week to week is an eye opener.
Sad truth is some jerks only care about money.
I care about seeing the BIXT antiviral technology get funded, approved and available to improve millions of lives and save millions of lives.
It is the ethical thing to do.
In one of your earlier post you indicated that Moderna needed funds and weeks later they were funded. I was one of the early investors in Moderna, correction, Moderna had 500 million in the coffers before Covid became a thing, plus pipelines going through the roof, until they were funded by the Government for their Covid vaccine. If this company truly has the science, they should have a partner to payoff the toxic notes.
$BIXT had three golden crosses already. Nice peeerdy Money green curve back up late today and the gap up covered
**Huge update on $BIXT just out. Also the First Lady of the USA has Covid, announced late yesterday.** BIXT is in the buying zone, and not many cheap shares left before this makes a huge run IMO.
https://www.linkedin.com/pulse/small-pharma-poised-find-next-wonder-drug-after-big-pharmas-sheikh/
Please copy and paste this everywhere! Personally email friends and social influencers to get this important meghage out!
https://www.linkedin.com/pulse/small-pharma-poised-find-next-wonder-drug-after-big-pharmas-sheikh/
The news of Covid was in national news today folks. The First Lady of the USA tested Positive for Covid today. It is news, news wakes up peep world to buy Covid stocks early. BIXT as of about 10 days ago is the only new FDA IND approval and the only viable one targeting Long haul Covid, with a non toxic antiviral that eliminates (Per India trials) in 3 days with an IV that shows PCR negative in 3 days. Not 2 weeks, but 3 days!!!
Long haul covid cases caused by residual spikes or residual virus should be curable with the BIXT antiviral.
And that would be just this beginning for this new new non toxic class of antivirals. The flu (also a corona virus) would targeted next. Mutations of the viruses would not get around the BIXT antiviral(s) because of how they work.
For the math challenged folks, it is simple. Do you buy now in volume at .21 or wait to buy the same company shares at .38 or .50 later this week?
This Nasdaq stock, $Prds, has $$$$$$ and no tech now and needs to desperately fund something like $BIXT IMO, to save themselves.
https://seekingalpha.com/article/4605537-pardes-bioscience-seeking-strategic-alternatives
Last call for BIXT bargains 2.0
If I was any one of several big pharma firms, I would be dangling a $100 Mil dollar JV and marketing deal at BIXT management right now.
Early bird gets the worm.
Indeed it can, in fact, BIXT just may turn out to be the David to the Moderna Goliath...
I recall early 2020, before Covid19, Moderna looked like it was in serious funding trouble, with no product revenue yet.
That Changed in weeks in 2020.
This could be JV deal coming with Big Pharma and a Buy out for 20 Billion dollars at some point. Wall Street Money is asleep at the wheel here, good for us buyers...
They will wake up because of this news, they just move slow, the ones that fund this kind of tech the right way..
Takes time. Some are like quietly eating shares, bid sitting and nibbling at the ask.
Great to see volume back up and climbing and a near 200% rally off the low, needed to cool off Friday. I Love more for less... These last shares will look like gifts shortly.
Covid is here to stay, just like the flue. The difference is that the Non toxic antiviral technology $BIXT has will have repeat sales to 9 Billion people year round, for every new wave of Covid and it can be adapted for the Flu and future corona viruses and strains. $BIXT tech is non toxic.
It can used as an oral pill for Covid (India trial is in the last part of the phase III trial already) and the US FDA IND is the first and only viable Long Haul Covid trial.
The India trial data is saying it will work for long haul covid, because it works for covid.
I called the Moderna buy in March 2020, before most people new Covid was going to be a problem based on the science.
Now here is the catch. Covid is so wide spread now, and mutates so fast, and it is jumping from Humans to deer, and Mink and back to humans, with massive new mutations they will never get rid of it with vaccines. And they can not make and test and distribute vaccines fast enough.
BIXT's antiviral works differently that the vaccines.
The Vaccines do not block cell infection.
The BIXT non toxic antiviral drug blocks the Covid / corona spikes so they can not infect human cells.
So no matter how many mutations the Covid comes up with the BIXT will still block off the spikes and their ability to attach to and infect cells.
So Infected people, can take the pill or IV and be back at work on day 4.
The new waves, Covid mutations that evade the vaccines and natural immunity world wide will keep coming, so demand for the BIXT drug will be steady world wide.
The drug can also work on Other corona viruses like the flue. This is going to be the best thing since sliced bread.
Ask yourself common sense questions, I got into this a little while ago from 21-23 cents, still holding not much though, just 30,000 shares. I had Moderna at 17-18 right before covid hit 8000 shares long and was posting that stock was going to triple digit dollars and it did of course didn't hold to the top but sold between 30-35 dollars, one morning it was 500 dollars premarket, cause they had 50 plus pipeline and indications going through the roof. I asked myself this question, if these guys really have the science like some guy says they do, someone would come in and pay of all the toxic funders and aim to get them on Nasdaq where they could do quality direct offerings, 500,000 dollars from accredited institutional investment is not going to cut it. I am going to stay and see how India plays out for them. There is still dilution on this stock and it prevents it from going up. There is only one love story in the OTC.
How viable do you think Bioxytran will be after COVID abates? Just curious to see if this could also be a long term play(?)
On high watch for me but this one seems to be back on it's way down. Lovely.
$BIXT looks poised for a trip to $$ land folks.
They are the only FDA IND, approved drug trial for Long haul Covid, that "clears Covid in 3 days", and that is 100% non toxic.
Let that sink in people.
https://insiderfinancial.com/the-next-axcella-axla-squeeze-bioxytran-bixt/184558/
If it is true, this stock will even hit 10 dollars in the OTC, it will have similar run like ALP*P. No one wants to miss out on the next Moderna.
World Changing news on $BIXT for sure.........
Z
If this news truly has any merits to it, it will go viral and this could jump $4-5 range by Christmas.
$BIXT Major US FDA News. This can be the next Moderna, only way better, not a vaccine, and non toxic antiviral that blocks viruses from being able to attach to human cells and infect them. This is Nobel prize winnable Technology.
https://www.globenewswire.com/news-release/2023/08/24/2731222/0/en/Bioxytran-Announces-FDA-Clearance-of-its-IND-Application-for-ProLectin-M-in-Clinical-Trials.html
Z
Looks like $BIXT is taking off nicely...........
Z
Yes, and right now the BIXT stock should be making moves to trade in the dollar land per share.
They are already in part 2 of part III of a phase III trial in India testing the non toxic Galectin antiviral for Covid19 that is agnostic to the
Covid19 mutations (should work on all of them, on all Covid Sars mutations, past and future) and today announce an FDA approval of the
IND Investigational New Drug trial Approval in the US.
This should wake up the market and rally this to $4 IMO.
EcoMike: By 'HUGE' are you thinking, say, ten dollars per share--and if so, how long do you think it might take before the company gets there? This one looks like a thin trader which often means sudden spikes in both directions but I also like the fact that roughly 80% of the outstanding shares are tightly held...
By "HUGE" are you conjecturing a ten dollar PPS or thereabouts? And if so, what general timeline do you think it might be reached in? Don't worry; I am NOT taking your comments as investing advice...this is the OTC after all...
I totally sgree
Time to load the boat with BIXT folks, no only is it not getting any cheaper it is going way higher. Get in early, or miss the best deals
hopefully bottomed
I started buying more BIXT today. Bottom is in. The upside potential is huge
https://www.bioxytraninc.com/pipeline#prolectin-pipeline
https://www.bioxytraninc.com/degenerative-diseases
This could be the next Moderna in a few years, and become the new antiviral standard. Non toxic antivirals and other huge potential tech...
It's been crickets here for a while... will they ever start/finish their PIII trial?
This money should get clinical trials on schedule!
news Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
Press Release | https://www.otcmarkets.com/stock/BIXT/news?id=404047
$BIXT NEWS: Press Release- Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment
Published: June 12, 2023 at 9:02 a.m. ET
BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing anti-viral oral drugs to treat retroviruses like SARS-CoV-2 which cause COVID-19 and other viral diseases, announced that it has entered into a common stock purchase agreement with TRITON FUNDS LP for $500,000. The proceeds will help kickstart the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing. TRITON FUNDS is the second institutional investor aligning its investment strategy with the lead institutional investor Walleye Capital, LLC which was founded in 2005 and now has $5 billion plus of assets under management.
The funding is sufficient to reach the next milestone of a submission of a Phase 3 regulatory trial in India for mild to moderate COVID-19. Bioxytran's Clinical Research Organization (CRO) has indicated that dosing in the 40-patient trial is expected to commence within the month now that the funding is in place.
"As a cornerstone of our investment portfolio, TRITON FUNDS has been meticulously and strategically trying to build a robust position in Bioxytran over the past year", said Axel Olson, Equity Analyst and Entrepreneur in Residence at TRITON FUNDS. "Our investment not only serves to solidify our cost basis but, more importantly, empowers Bioxytran with the necessary capital infusion to propel them towards their impending milestone."
He added, "Having observed the company's trajectory for well over a year, we've been profoundly inspired by the tenacity and resilience of the management team, who have navigated with aplomb amidst a challenging regulatory and financial terrain. We are firm believers in the transformational potential of Bioxytran's technological prowess, a promising beacon that could drastically alter the treatment landscape for viral diseases. This investment represents our steadfast confidence in Bioxytran's capacity to usher in a new era in medical science."
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drugs called Galectin Antagonists designed to neutralize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com
About TRITON FUNDS
As the nation's premier student-managed fund, TRITON FUNDS empowers students with real-world experience in Venture Capital and Private Equity. Our millennial-driven, alternative investment strategies foster growth and transformation in promising industries. We champion a growth cycle that benefits students, investors, and the broader community. Discover more at www.tritonfunds.com.
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
Makes you want to buy more BIXT!
https://seekingalpha.com/article/4605537-pardes-bioscience-seeking-strategic-alternatives
I, too, lost a lot money on the CYDY debacle! It was awful! And yes, the communications officer for Bioxytran was writing articles for them.
This is a Bioxytran and they have a number of drugs in the pipeline and a device that could literally change the world when it comes to viruses cancer, stroke, heart attack, TBI, sickle cell anemia and many other indications!
Look at the company, look at their products look at the CEO!
Of course you did. Their VP of BS is the sheikh of nodderspeak. Pumped the indicted felon CEO of CYDY for years. He should be indicted for his pumper lies also. Good luck ms sooey
Science behind the product:
Bioxytran has a significant subject matter expertise in the formulation of an oral form of a Galectin inhibitor. The company was able to capitalize on Dr Platt’s many years of research and recent peer reviewed articles on Galectins and COVID-19 to quickly complete the proof of concept phase. Dr Platt, who has a PhD in carbohydrate chemistry, was the first scientist to express the gene, which he named Galectin, 28 years ago.
We know that the N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein scientists have elucidated a galectin fold on the side of the spike that should have a binding affinity to sugar carbohydrates like ProLectin. Animal studies on influenza (needs reference) have demonstrated that inhibiting galectin-1 improves outcomes in lethal influenza models. Other animal’s models show that galectin inhibitors act as immune modulators in cancer and other diseases.
Our molecule is designed to stay in the blood and attach to the COVID-19 protein spikes. When the inhibitor binds to the spike it effectively tags the virus for elimination through the liver. Galectins are theorized to participate in the antiviral defense which starts at the initial recognition of the virus before it binds to the entry receptor all the way through the activation and amplification of the innate and adaptive responses of the immune system.
Galectins are adhesion molecules and allow neutrophils to stay prepositioned in the pulmonary capillaries for a quicker reaction in case of infection. They are also involved in the trafficking of macrophages responsible for the inflammatory cycle of the cytokine storm. Additionally, research in cancer and viruses has demonstrated that galectins form a plaque on CD-8 T-cells which inhibit the adaptive immune response. Therefore, our galectin antagonist should not only reduce the viral load of COVID-19, but also modulate the immune response by reducing the trafficking of macrophages thereby reducing the cytokine storm and returning the immune system to homeostasis. We also expect it to restore functionality to the adaptive immune system by reactivating anergic T-cells that were covered in galectin plaque.
If given early in the disease, we believe that our first drug candidate, galectin antagonist, will block viral entry and tag the virus for elimination through the liver. In theory the virus will be eliminated from the blood stream after a couple of treatments. At a later stage in the disease pathology, a more potent IV solution, ProLectin- I could restore adaptive immune function to help eradicate the virus from the body. In severe COVID-19 patients the drug, ProLectin-A, could reduce the trafficking of macrophages responsible for the cytokine storm and restore immune homeostasis. ProLectin-F is designed to treat organ damage after virus is eliminated from the system.
Galectin Antagonist is the first-in-class of inhibitors to cover a range of Galectins associated with viral replication adhesion and immune system blockage (not modulation). The N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein the Galectin fold on the side of the spike has a binding affinity to sugar carbohydrates like Galectin Antagonist.
Galectins are members of a family of proteins called lectins. These proteins interact with carbohydrate sugars located on the surface, in between cells, and on the Galectin fold of the spike protein. These interactions cause the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain (CRD), within the lectins. Galectins have a CRD that binds specifically to sugar molecules. They have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections Galectins are upregulated and downregulated based on the type of virus.
Bioxytran intends to develop and, through third party contracts, manufacture oxygen therapeutics. Our oxygen therapeutics are a new class of pharmaceuticals that are administered intravenously to transport oxygen to the body’s tissues. Currently there are four drug candidates to treat a stroke. Abciximab from Eli Lilly is a platelet aggregation inhibitor. Clinical trials show little advantage over placebos and could lead to dangerous side effects, including more bleeding in patients. Cerovive from AstraZeneca is a Nitrone-based neuro protectant currently in phase III clinical trials which shows no significant benefit over placebos with respect to changes in neurological impairment as measured by the national institute of health stroke scale. Candesartan, from AstraZeneca, is an angiotensin receptor blocker which was used to control blood pressure. Its efficacy in stroke patients still must be proven. Ancod from Knoll Pharmaceuticals is an anti-coagulant that acts by breaking down the fibrinogen. It increases the risk of hemorrhage similar to those associated with tPA. Using our issued patents and proprietary technology, we intend to develop and manufacture BXT-25 and similar drugs for applications including treatment of stroke conditions. Our patent position consists of 2 parts: a patent related to our co-polymer technology issued in 2009 by the United States Patent and Trademark Office expiring in February 2029 (method patent for producing modified pectins consisting of neutral sugar sequences ) and assigned to us outright by David Platt; various methods to stabilize a single hemoglobin molecule that are in the public domain; Dr. Platt did not receive any compensation from the Company in consideration of his assignment of the patent. Additionally, Bioxytran, Inc. has an exclusive license for an FDA approved technology monitoring NADH (OxySense), the control marker in the body’s conversion of Oxygen to Energy, or the energy generating chain. The technology provides a clinical end-point for measuring oxygen supply to the brain in real-time. OxySense, developed by MDX LifeSciences, Inc., provide us with a rapid, cost-effective and validated development of safe new molecules that address unmet medical needs in disease indications resulting from hypoxia. MDX LifeSciences has licensed a patent (Tissue Metabolic Score for Patient Monitoring) to Bioxytran for clinical monitoring of oxygen delivery through oxygen carriers.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |